<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Why Moderna (MRNA) Stock Is Trading Up Today — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Why Moderna (MRNA) Stock Is Trading Up Today</h2>
    <div class="badge">2025-09-16T15:40:49+00:00</div>
    <ul>
      <li>After the initial pop the shares cooled down to $24.74, up 3.6% from previous close.</li>
<li>Moderna is down 41.1% since the beginning of the year, and at $24.74 per share, it is trading 65.6% below its 52-week high of $71.99 from September 2024.</li>
<li>Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced positive preliminary data for its updated 2025-2026 COVID-19 vaccine, Spikevax®.</li>
<li>Moderna’s shares are extremely volatile and have had 50 moves greater than 5% over the last year.</li>
<li>Further bolstering investor confidence, UBS reiterated its &#x27;Buy&#x27; rating and a $70 price target on the stock.</li>
<li>Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $359.38.</li>
<li>The previous big move we wrote about was 4 days ago when the stock dropped 7.8% as reports revealed Trump administration health officials plan to link COVID-19 vaccines to the deaths of around two dozen children.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Why Moderna (MRNA) Stock Is Trading Up Today\n• After the initial pop the shares cooled down to $24.74, up 3.6% from previous close.\n• Moderna is down 41.1% since the beginning of the year, and at $24.74 per share, it is trading 65.6% below its 52-week high of $71.99 from September 2024.\n• Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced positive preliminary data for its updated 2025-2026 COVID-19 vaccine, Spikevax®.\n• Moderna’s shares are extremely volatile and have had 50 moves greater than 5% over the last year.\n• Further bolstering investor confidence, UBS reiterated its &#x27;Buy&#x27; rating and a $70 price target on the stock.\n• Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $359.38.\n• The previous big move we wrote about was 4 days ago when the stock dropped 7.8% as reports revealed Trump administration health officials plan to link COVID-19 vaccines to the deaths of around two dozen children." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/why-moderna-mrna-stock-trading-154049148.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>